Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BI’s Business Development Focus Remains On Early Collaboration

Executive Summary

Boehringer Ingelheim’s US business development head Ioannis Sapountzis outlines BI’s efforts to catch up with competitors in NASH and immuno-oncology via early-stage partnerships and licensing deals.

Advertisement

Related Content

Boehringer Ingelheim Is Getting Bets In Early In IO Space
Biopharma Quarterly Dealmaking Statistics, Q2 2018
Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack
OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List
Boehringer Ingelheim Confident Of A Happier Ending In NASH Than HCV
Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel